



This is a marketing communication

Liontrust GF UK Growth Fund

June 2023 review

Fund managers: Anthony Cross and Julian Fosh

The Liontrust GF UK Growth Fund returned 0.5%* in June. The Fund's comparator benchmark, the FTSE All-Share, returned 1.0%.

The direction of interest rates was once again the primary market narrative in June. The US Federal Reserve's decision to hold rates steady at a 5.0% to 5.25% target range after 10 consecutive hikes was communicated as merely a pause in the pace of tightening, and a hawkish one at that, with its rate-setting committee forecasting 50 basis points (bps) of additional increases by the end of the year.

There was no let up in the tightening cycle in Europe, where the European Central Bank increased rates by 25bps to 3.5%, or the UK, where the Bank of England surprised with a 50 basis point hike – its 13th consecutive increase – to 5.0% after headline consumer price inflation remained stubbornly high at 8.7% in May, the same level as April and defying forecasts of an easing to 8.4%. By the end of May, futures prices were suggesting the Bank of England base rate will continue to rise to a peak of 6.25% early in 2024.

The emergence of country-specific factors – such as Brexit-related labour shortages – which have driven expectations of UK inflation and interest rates higher than many other developed markets has coincided with a period of relative strength for the typically more internationally diversified FTSE 100 large-cap index. The FTSE 100 returned 1.4% in June, outperforming the FTSE 250 mid-cap index's -1.3% return. Since the start of 2022, the FTSE 100 has now outperformed the FTSE 250 by 23 percentage points.

Around two thirds of the Fund is invested in large-caps, leaving it underweight versus the FTSE All-Share's 83% exposure to FTSE 100 stocks. The majority of the remainder of the portfolio (around 20%) is invested in mid cap stocks, with the small cap component capped at a maximum of 10% (currently around 6%). We believe many of our mid and small caps can already be considered genuinely global businesses, with all the benefits of geographic diversification and growth runway which that entails. In fact, data from Factset estimates the portfolio's overseas sales exposure to be around 83%, in excess of the FTSE All Share benchmark's 77%, despite its modestly greater weighting further down the market cap scale.

Amid a fairly light month for portfolio newsflow, **Paypoint** (+25%) and **Indivior** (+25%) registered strong gains on the back of short updates.

A trading update from **Paypoint** (+25%) confirmed its prior estimate of £125m revenue in the year to 31 March and upgraded profits guidance to the top end of market expectations. Shares in the convenience store payments and e-commerce specialist have de-rated somewhat since announcing the acquisition of gift card group Appreciate late last year, but regained some impetus from June's statement. Paypoint commented that the integration of Appreciate has progressed well, and has accelerated its ability to create enterprise-level product packages.

Indivior (+25%) rallied as some legacy risks around its marketing of products in the US crystallised. *Suboxone*, formerly the company's leading product, has been the subject of multi-state litigation in the US for several years, but it has now reached a settlement to pay \$103m. The payment will be recorded against a \$290m balance sheet provision which Indivior had previously set aside.

While legal risks have represented an overhang for Indivior shares for some time, its prospects are increasingly linked to the growth of its next generation *Sublocade* opioid addiction treatment, which has consistently exceeded sales expectations and now exceeds *Suboxone* sales.

Although it delivered 21% growth in sales to £1.8bn in the year to 31 March 2023, **Halma** (-5.5%) saw some compression in margins which restricted adjusted profit before tax growth to 14% (to £361m). Some of its divisions experienced supply chain disruption in the second half of the year, but these are expected to ease in the new financial year.

Positive contributors included:

Indivior (+25%), Paypoint (+25%), Brooks Macdonald Group (+16%), TI Fluid Systems (+12%) and Sage Group (+7.0%).

Negative contributors included:

Synthomer (-19%), Next 15 (-8.7%), PageGroup (-7.7%), Savills (-6.5%) and Halma (-5.5%).

Discrete years' performance (%), to previous quarter-end:**

Past performance does not predict future returns

	Jun-23	Jun-22	Jun-21	Jun-20	Jun-19
Liontrust GF UK Growth C3 Inst Acc GBP	5.8%	2.2%	17.2%	-9.4%	2.7%
FTSE All Share	7.9%	1.6%	21.5%	-13.0%	0.6%

	Jun-18	Jun-17	Jun-16
Liontrust GF UK Growth C3 Inst Acc GBP	10.8%	18.9%	8.2%
FTSE All Share	9.0%	18.1%	2.2%

*Source: Financial Express, as at 30.06.2023, total return (net of fees and income reinvested), sterling terms, C3 institutional class. Non fund-related return data sourced from Bloomberg.

**Source: Financial Express, as at 30.06.2023, total return (net of fees and income reinvested), primary class. Discrete data is not available for ten full 12-month periods due to the launch date of the portfolio (03.09.14). Investment decisions should not be based on short-term performance.

Key Features of the Liontrust GF UK Growth Fund

Investment objective & policy ¹	The investment objective of the Fund is to provide long term capital growth by investing predominantly in UK equities. The Fund invests at least 80% in securities of companies traded on the UK and Irish stock exchanges. The Fund invests predominantly in UK large and mid-cap stocks.
Recommended investment horizon	5 years or more
Risk profile (SRRRI) ²	5
Active/passive investment style	Active
Benchmark	The Fund is considered to be actively managed in reference to the FTSE All Share Index (the "Benchmark") by virtue of the fact that it uses the Benchmark for performance comparison purposes. The Benchmark is not used to define the portfolio composition of the Fund and the Fund may be wholly invested in securities which are not constituents of the Benchmark.

Notes: 1. As specified in the KIID of the fund; 2. SRRRI = Synthetic Risk and Reward Indicator. Please refer to the KIID for further detail on how this is calculated.

For a comprehensive list of common financial words and terms, see our glossary at:
<https://www.liontrust.co.uk/glossary>

Key Risks:

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

Disclaimer

Non-UK individuals: This document is issued by Liontrust International (Luxembourg) S.A., a Luxembourg public limited company (société anonyme) incorporated on 14 October 2019 and authorised by and regulated as an investment firm in Luxembourg by the Commission de Surveillance du Secteur Financier (“CSSF”) having its registered office at 18, Val Sainte Croix, L-1370 Luxembourg, Grand Duchy of Luxembourg and registered with the Luxembourg trade and companies register under number B.238295. UK individuals: This document is issued by Liontrust Fund Partners LLP (2 Savoy Court, London WC2R 0EZ), authorised and regulated in the UK by the Financial Conduct Authority (FRN 518165) to undertake regulated investment business. **This is a marketing communication.** It should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust. Always research your own investments and if you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.

[23/421]